| 摘要 |
The disclosure relates products composed of a component A, a compound of general formula (I) in which the substitution pattern is disclosed within the specification, and component B an active compound of one of the following active compound groups: (I-2) GABA-gated chloride channel antagonists; (I-3) sodium channel modulators/voltage-dependent sodium channel blockers; (I-4) nicotinergic acetylcholine receptor agonists; (I-5) allosteric acetylcholinereceptor modulators (agonists); (I-6) chloride channel activators; (I-17) octopaminergic agonists;(I-25) synergists such as MGK264 and piperonyl butoxide (PBO). These products are for use against ectoparasites on animals. Examples of component A include: 4-(7 -chloro-,3-benzodioxol-5-yl)-1-(3-ethoxypyrazin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-5-amine 4-(7 -chloro-1,3-benzodioxol-5-yl)-1-(3-methoxypyrazin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-5-amine 4-(7-chloro-1,3-benzodioxol-5-yl)-1-(3-methoxypyrazin-2-yl)-3-methyl-1H-pyrazole-5-amine 4-(7-chloro-1,3-benzodioxol-5-yl)-1-(3-ethoxypyrazin-2-yl)-3-ethyl-1H-pyrazole-5-amine 4-(7-chloro-1,3-benzodioxol-5-yl)-1-(3-methoxypyrazin-2-yl)-3-cyclopropyl-1H-pyrazole-5-amine 4-(7-bromo-1,3-benzodioxol-5-yl)-1-(3-ethoxypyrazin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-5-amine 4-(7-bromo-1,3-benzodioxol-5-yl)-1-(3-methoxypyrazin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-5-amine 4-(7-bromo-1,3-benzodioxol-5-yl)-1-(3-ethoxypyrazin-2-yl)-3-ethyl-1H-pyrazole-5-amine 1-(3-ethoxypyrazin-2-yl)-3-(triluoromethyl)-4-[7-(trifluoromethyl)-1,3-benzodioxol-5-yl]-1H-pyrazole-5-amine 4-(3,5-dichloro-4-methoxyphenyl )-1-(3-ethoxypyrazin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-5-amine 4-[3,5-dichloro-4-(dimethylamino)phenyl]-1-(3-ethoxypyrazin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-5-amine: |
